bluebird bio, Inc. (BLUE)
Jun 2, 2025 - BLUE was delisted (reason: acquired by Carlyle and SK Capital)
4.970
0.00 (0.00%)
Inactive · Last trade price
on May 30, 2025
bluebird bio Revenue
bluebird bio had revenue of $38.71M in the quarter ending March 31, 2025, with 108.43% growth. This brings the company's revenue in the last twelve months to $103.95M, up 127.51% year-over-year. In the year 2024, bluebird bio had annual revenue of $83.81M with 184.12% growth.
Revenue (ttm)
$103.95M
Revenue Growth
+127.51%
P/S Ratio
0.46
Revenue / Employee
$419,137
Employees
248
Market Cap
48.67M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBLUE News
- 5 days ago - bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital - Business Wire
- 8 days ago - Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer - Business Wire
- 11 days ago - bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital - Business Wire
- 21 days ago - Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions - Business Wire
- 24 days ago - Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital - Reuters
- 24 days ago - Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement - Business Wire
- 4 weeks ago - Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital - Business Wire
- 4 weeks ago - Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio - Business Wire